Physician profile
Michael Chau
NPI 1588036719
$2,196.24
in general payments reported to CMS, 2019-2025
16 companies · $87.41 in 2025
The $87.41 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.59 · 2021: $134 · 2022: $833 · 2023: $699 · 2024: $347 · 2025: $87.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125 · Education: $8.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.98 |
| Education | $8.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $528.45 | 2019-2023 | Lokelma, Farxiga |
| Stryker Corporation | $253.20 | 2024-2025 | Na |
| Glaxosmithkline, LLC. | $223.11 | 2022-2024 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $205.70 | 2021-2023 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $156.49 | 2022-2023 | Velphoro |
| Horizon Therapeutics Plc | $153.24 | 2022-2023 | |
| Saxum Surgical, INC. | $140.70 | 2022 | |
| Travere Therapeutics, INC. | $127.93 | 2024-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $94.94 | 2022-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $86.66 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.77 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $59.05 | 2021-2023 | Acthar |
| Calliditas Therapeutics US INC. | $39.46 | 2022 | |
| Amgen INC. | $24.28 | 2023 | Tavneos |
| Alexion Pharmaceuticals, INC. | $21.68 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $18.58 | 2024 | Maci |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.